
|
Channels
|
||||
|
Medical Health Encyclopedia
Lyme Disease and Related Tick-Borne Infections - Complications
From Healthscout's partner site on osteoarthritis, HealthCentral.com
(Page 3) Post-Lyme Disease SyndromeLyme disease is a curable condition. Nearly all patients (95%) improve after a short course of antibiotics. In very rare cases, patients continue to complain of persistent non-specific symptoms such as fatigue, muscle aches, cognitive problems, and headache lasting years after completing antibiotic treatment for the initial infection. This syndrome, which resembles chronic fatigue syndrome (CFS) or fibromyalgia, is referred to as post-Lyme disease syndrome. In the past, it has been called “chronic Lyme disease.” However, based on many reviews of scientific literature, experts strongly believe that Lyme disease does not have a chronic state. According to the 2006 guidelines from the Infectious Diseases Association of America, post-Lyme disease syndrome is the preferred name for this condition. ![]() Patients are considered to have this syndrome if they still have symptoms 6 months after treatment. Most importantly, there must be definitive evidence that the patient was originally infected by the B. burgdorferi spirochete. If there is no documented evidence of infection, it could be that the patient never had Lyme disease, or may be experiencing a new or different type of illness. If the patient did have Lyme disease, symptoms should eventually resolve without additional antibiotic treatments. Experts strongly advise against prolonged antibiotic treatment. There is no evidence that long-term antibiotics help treat post-Lyme disease syndrome symptoms. In addition, long-term antibiotic treatment carries its own serious risks, such as the development of antibiotic-resistant superbugs.
Review Date: 01/18/2007 A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). ![]() | ||||
|
Search
Health Tools
Featured Conditions
Resources
Find a Therapist
PR Newswire
|
New Features
|
|||
|
||||